Anti-obesity drug discovery: advances and challenges
Enormous progress has been made in the last half-century in the management of diseases
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …
closely integrated with excess body weight, such as hypertension, adult-onset diabetes and …
[HTML][HTML] GLP-1 receptor agonists in the treatment of type 2 diabetes–state-of-the-art
MA Nauck, DR Quast, J Wefers, JJ Meier - Molecular metabolism, 2021 - Elsevier
Background GLP-1 receptor agonists (GLP-1 RAs) with exenatide bid first approved to treat
type 2 diabetes in 2005 have been further developed to yield effective compounds …
type 2 diabetes in 2005 have been further developed to yield effective compounds …
[HTML][HTML] Glucagon-like peptide 1 (GLP-1)
TD Müller, B Finan, SR Bloom, D D'Alessio… - Molecular …, 2019 - Elsevier
Background The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose …
GLP− 1 receptor agonists for the treatment of obesity: Role as a promising approach
JY Wang, QW Wang, XY Yang, W Yang… - Frontiers in …, 2023 - frontiersin.org
Obesity is a complex disease characterized by excessive fat accumulation which is caused
by genetic, environmental and other factors. In recent years, there has been an increase in …
by genetic, environmental and other factors. In recent years, there has been an increase in …
[HTML][HTML] Semaglutide lowers body weight in rodents via distributed neural pathways
S Gabery, CG Salinas, SJ Paulsen, J Ahnfelt-Rønne… - JCI insight, 2020 - ncbi.nlm.nih.gov
Semaglutide, a glucagon-like peptide 1 (GLP-1) analog, induces weight loss, lowers
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …
glucose levels, and reduces cardiovascular risk in patients with diabetes. Mechanistic …
[HTML][HTML] Anxiety, depression, and the microbiome: a role for gut peptides
The complex bidirectional communication between the gut and the brain is finely
orchestrated by different systems, including the endocrine, immune, autonomic, and enteric …
orchestrated by different systems, including the endocrine, immune, autonomic, and enteric …
[HTML][HTML] The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission
Growing evidence indicates that the glucagon-like peptide-1 (GLP-1) system is involved in
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …
the neurobiology of addictive behaviors, and GLP-1 analogues may be used for the …
Ghrelin, CCK, GLP-1, and PYY (3–36): secretory controls and physiological roles in eating and glycemia in health, obesity, and after RYGB
The efficacy of Roux-en-Y gastric-bypass (RYGB) and other bariatric surgeries in the
management of obesity and type 2 diabetes mellitus and novel developments in …
management of obesity and type 2 diabetes mellitus and novel developments in …
Effects of once‐weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity
J Blundell, G Finlayson, M Axelsen… - Diabetes, Obesity …, 2017 - Wiley Online Library
Aim The aim of this trial was to investigate the mechanism of action for body weight loss with
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …
semaglutide. Materials and methods This randomised, double‐blind, placebo‐controlled …
Pharmacotherapy of obesity: available medications and drugs under investigation
Obesity is a chronic disease with a continuously rising prevalence that currently affects more
than half a billion people worldwide. Energy balance and appetite are highly regulated via …
than half a billion people worldwide. Energy balance and appetite are highly regulated via …